BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

Biotechnology

BenevolentAI

Joerg Moeller

James Malone

Christina Busmalis

Amy Gibson

Eve Berry

Catherine Isted

Atima Bhatnagar

Jane McGuffog

Tom Holgate

Anna Fullerton-Batten

Fleur Wood

Nicola Richmond

Ed Savory

Nikki Robas

Constantinos Neophytou

Peter Richardson

Catherine Tucker

Will Scrimshaw

Ivan Griffin

Anne Phelan

Neal Lewis

James Dunbar

The current leadership team at BenevolentAI has a wide range of experience in both the public and private sectors. They have experience working in industries such as consulting, artificial intelligence, and pharmaceuticals. They also have a variety of educational backgrounds, including computer science, mathematics, and machine learning.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at BenevolentAI

Board of Directors

CEO and Executive Team